]>
IRCT201701162709N39 IRCT 2017-05-06 Vice Chancellor for Research of Iran university Medical Sciences The effect of sumacl on fatty liver disease The effect of supplementation with sumac powder on liver enzymes (Alanine aminotransferase and Aspartate aminotransferase ), lipid profiles(Triglyceride,Total cholestrol,High density lipoprotein,Low density lipoprotein)، leptin and liver steatosis in patients with non-alcoholic fatty liver disease: a randomized controlled clinical trial 2017-02-19 anticipated 80 Complete https://irct.ir/trial/2550 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive. N/A Nonalcoholic fatty liver. Intervention 1: Control group: daily 2 g dextrin as 4 capsules of 500 mg. Intervention 2: Intervention group: daily 2 g sumac as 4 capsules of 500 mg.
public Dr Farzad Shidfar
School of Public Health,Iran University Medical Sciences,The intersection of Sheikh Fazllolallah and shahid Chamran,Hemmat Highway,Tehran
Tehran Iran (Islamic Republic of) +98 21 8670 4743 Shidfar.f@iums.ac.ir, farzadshidfar@yahoo.com, siminehsani@ymail.com Iran University Medical Sciences scientific Dr Farzad Shidfar
School of Public Health,Iran University Medical Sciences,The intersection of Sheikh Fazllolallah and shahid Chamran,Hemmat Highway,Tehran
Tehran Iran (Islamic Republic of) +98 21 8670 4743 Shidfar.f@iums.ac.ir, farzadshidfar@yahoo.com, siminehsani@ymail.com Iran University Medical Sciences Iran (Islamic Republic of) The criteria for inclusion: Age 20-60 years of both sexes, fatty liver disease be approved by physician gastroenterologist based on the following criteria: (ultrasound, volume Alastvmtry in fiberscan and> 4 kPa (kpa) or are in the process of steatosis S1 and Alanine transferase more than 5.1 times the upper limit of normal (women and men), Body Mass Index (BMI)25-29/9), a interested in participating the plan and received written informed consent, lack of participation in other projects. Exclusion criteria:The patient's unwillingness to continue cooperation with the Started taking the drug during the intervening period, Change the type or dose, Change in diet or physical activity program, Weight loss more than 10% of initial body weight during the intervention , Any use of antioxidant supplements, vitamins or minerals , Less than 80% supplements delivered to the patient at baseline, Start smoking during the intervening period, Become pregnant during treatment, Surgery and psychosomatic problems during the intervention, The use of all anti-NASH (vitamin E, thiazolidinedione, UDCA gemfibrozil,), Developing other liver diseases, kidney, kidney stones, cancer, hypothyroidism or hyperthyroidism, allergies, trauma during the intervention 20 years 60 years Both K76.0 Fatty (change of) liver, not elsewhere classified Treatment - Drugs Treatment - Drugs Control group: daily 2 g dextrin as 4 capsules of 500 mg Intervention group: daily 2 g sumac as 4 capsules of 500 mg Alanine aminotransferase. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry. Aspartate aminotransferase. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry. Hepatic steatosis. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Using the scanning fiber 502. Total cholestrol. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry. Triglycerides. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry. Low density lipoprotein. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry. High density lipoprotein. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry. Leptin. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Elisa. Vice Chancellor for Research of Iran university Medical Sciences Approved 2016-11-08 The ethics committee the University of Medical Sciences Iran School of Public Health,Iran University Medical Sciences,The intersection of Sheikh Fazllolallah and shahid Chamran,Hemmat Highway,Tehran Tehran Iran (Islamic Republic of)